BioSpace News Archive

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the independent members of the Merck Board of Directors have appointed Thomas H. Glocer as independent lead director effective immediately.

Flamingo Therapeutics., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that Mike Garrett, Chief Executive Officer and Rob MacLeod, Chief Scientific Officer, will participate in a fireside chat at the Chardan Virtual 5th Annual Genetic Medicines Conference on Monday, October 4th, 2021 at 5:30 pm ET.

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in a panel discussion during the 2021 Maryland Life Sciences Bio Innovation Conference.

Each option is exercisable into one common share at a price of $0.30 per share and will vest at the rate of 25% every six months.

Scientific Industries, Inc. announced that it will present at the Lytham Partners Fall 2021 Investor Conference on Tuesday, October 5, 2021 at 4:15 PM ET.

MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that it has entered into a sale-leaseback transaction with an affiliate of Creative Manufacturing Properties, which will generate $102.25 million in gross proceeds upon closing.

IntelGenx Corp. (TSXV:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that its co-development and commercialization partner for Tadalafil oral films for the treatment of erectile dysfunction (“ED”) and benign prostatic hyperplasia (BPH) (the “Product”), Aquestive Therapeutics, Inc. (NASDAQ:AQST) (“Aquestive”), has entered into a definitive license and supply agreement (the “Agreement”) with an undisclosed leading men’s health company.

ANP Technologies, Inc. (ANP) announced the termination of the binding acquisition Term Sheet with Sorrento Therapeutics, Inc. (SRNE), effective September 28, 2021.

Medsenic, a clinical-stage biopharmaceutical company specializing in the discovery and development of new indications and formulations of arsenic salts for the treatment of severe autoimmune diseases, today announced that it has received from the US Patent and Trademark Office (USPTO) with Arscimed®,

ILiAD Biotechnologies, LLC (ILiAD) presented a breakthrough finding today on the effect of BPZE1, a live attenuated intranasal pertussis vaccine, on serum bactericidal activity (SBA) against PRN(+) and PRN(-) Bordetella pertussis strains at the virtual ID Week 2021 conference (sponsored by Infectious Disease Society of America).